It is noteworthy to mention that anti-PD-1 therapies are approved for treating solid tumors characterized by microsatellite instability-high (MSI-H), mismatch repair deficiency (dMMR), or high tumor mutation burden (TMB-H), including GBM [90]. This evidence concerns the gene PDCD1 and glioblastoma.